For instance, low expression of CDX2 is a predictive marker for chemosensitivity,8 mutations in PTPRT serve as a potential predictive marker for metastatic CRC,7 mutations in BRAF V600E is a prognostic factor for stage II microsatellite stable (MSS) CRC,9 and mutations in KRAS or BRAF are associated with worse outcomes for patients with stage III MSS CRC.10, 11. This evidence concerns the gene PTPRT and colorectal carcinoma.